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population with asthma. RESULTS: We found 18 articles that
met the inclusion criteria; three were validation studies and the
remaining were observational studies or clinical trials. All three
domains of the SGRQ are internally consistent and reliable with
ICC of at least 0.70 for individual domains and greater than 0.90
for total score. Convergence and discriminate validity were seen
with two of three domains and dyspnea grade, six-minute walk
distance, and other HRQoL instruments. Face and content valid-
ity were demonstrated. SGRQ was able to discriminate between
patients with varying levels of symptoms, FEV1, self-reported
healthcare utilization services, asthma control problems, and
HRQoL. Responsiveness to change, however, is not well-
established for SGRQ despite a reported minimally important
difference of 3.9-unit change, which may be due partly to a
paucity of studies using SGRQ in this population. CONCLU-
SIONS: Our ﬁndings suggest SGRQ has face, content, and con-
struct validity. It is able to discriminate between different groups
of asthma patients, and may be useful in facilitating asthma
resource allocation. Further research is needed to determine its
responsiveness to change.
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OBJECTIVE: We applied the extension of propensity score
methodology that allows for estimation of average causal effects
with multi-valued treatment. METHODS: The methodology
requires three steps: 1. Estimating propensity score with multin-
omial or nested logit 2. Estimating the conditional expectation
and 3. estimate average respond treatment by calculating average
of conditional expectation averaged over the distribution of the
pre-treatment variables. RESULTS: The Market Scan private
insurance data base was used in this study which based upon
asthma individuals whose health care was provided under a
variety of fee-for-service (FFS), fully capitated and partially cap-
itated health plans, including exclusive provider organizations,
indemnity plans. Treatment is divided into three categories: a)
controller only; b) reliver only; and c) reliever and controller.
These three categories is matched with control group using mul-
tionomial logit. Pre-period demographic and clinical factors are
used as a covariate. Conditional expectations are calculated and
applied as a weight to estimate average treatment effect among
asthma patients. Reliever and Controller patients have 
the highest treatment effect whereas controller only patients have
the lowest effect. CONCLUSION: Multi-valued treatment is
common in pharmacoeconomical research and extension of
propensity score matching to cover multi-valued treatment is
straightforward and easy to apply.
ASTHMA—Patient Reported Outcomes
PAS12
TREATMENT PERSISTENCE AND COMPLIANCE WITH
MEDICATIONS FOR ASTHMA AND CHRONIC OBSTRUCTIVE
PULMONARY DISEASE
Cramer JA1, Bradley-Kennedy C2, Scalera A3
1Yale University School of Medicine, West Haven, CT, USA,
2Boehringer Ingelheim (Canada) Ltd, Burlington, ON, Canada, 3Pﬁzer
Canada Inc, Kirkland, ON, Canada
OBJECTIVE: To assess the patterns of persistence with various
classes of inhaled medications (i.e., beta agonist, anticholinergic,
and glucocorticoid) medications used to treat asthma and
chronic obstructive pulmonary disease (COPD). METHODS:
Pharmacy claims data were analyzed for persistence with inhaled
treatment (time to discontinuation) using a 60-day gap to deﬁne
discontinuation. Compliance, deﬁned as the percentage of days
with doses available divided by days to last reﬁll, also was
assessed. Patients were grouped as naïve (no inhaled medication
in the previous year) or experienced (previous or current treat-
ment), and by age (18–65, 65+ years). Medications included:
ipratropium, ipratropium + salbutamol, formoterol, formoterol
+ budesonide, salmeterol, salmeterol + ﬂuticasone, and
tiotropium. RESULTS: The database included 31,368 patients
prescribed one of these medications (4,888 naïve, 26,480 expe-
rienced). Based on a 60-day lapse in reﬁll, only 15–63% of
patients continued on the index drug for more than 6 months,
further decreasing to 7–53% at 12 months, and 5–47% at 18
months. At 12 months, patients taking tiotropium had signiﬁ-
cantly longer persistence rates compared to that for other drugs
(53% versus 7–30%, all p < 0.0001), and fewer switches to alter-
native medications. Naïve patients had signiﬁcantly shorter treat-
ment persistence than experienced patients for all drugs (all p <
0.0001), including tiotropium (27% versus 55%, p < 0.0001).
Compliance rates were similar for all drugs (i.e., 76%–94%) but
highest for tiotropium. CONCLUSIONS: These data demon-
strated that 1) persistence with inhaled treatment for asthma and
COPD was low overall (despite the generous 60-day allowance
to reﬁll), but patients stayed on treatment with tiotropium sig-
niﬁcantly longer than with other medications, and 2) patients
naïve to these classes of inhaled treatment had shorter treatment
persistence than experienced patients.
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Asthma is a chronic inﬂammatory disorder of the lungs and has
a signiﬁcant impact on morbidity, mortality, and health-related
quality of life (HRQL). Asthma also impacts indirect costs result-
ing from losses in workplace productivity. OBJECTIVE: To
examine the association of medication adherence with workplace
productivity and HRQL in patients with asthma in a state health
insurance program. METHODS: The diagnosis of asthma was
identiﬁed from medical claims data of state employees between
18 and 65 years of age who obtained healthcare beneﬁts from a
state health insurance program from July 2001 through June
2003. A three-part survey was mailed to these patients to
measure HRQL, workplace productivity, (absenteeism [time lost
from work] and presenteeism [reduced productivity at work]),
and self-reported medication adherence. The survey consisted of
the St. George’s Respiratory Questionnaire, the Workplace Pro-
ductivity Short Inventory, and the Morisky Adherence Scale. Pro-
ductivity losses were translated into dollar values by using
previously published metrics (employer perspective). The associ-
ation between self-reported medication adherence and HRQL
and productivity was measured using multivariate regression
analyses. RESULTS: The response rate was 25.1% (385/1493).
The mean HRQL total summary score was 33.2 ± 19.9 units,
with the symptoms domain having the worst HRQL scores (49.3
± 21.4 units), followed by the activity (39.6 ± 26.6) and impacts
(24.6 ± 19.1) domains. 39% of the participants reported them-
selves as “high” adherent, 19% reported themselves as
“medium” adherent, and 42% as “low” adherent. Asthma
resulted in productivity losses of $597 ± $1024 (absenteeism)
